T-Net: Home

Member Login
|
Employer Login

BC Tech News ▼
International ▼
Member Tools ▼
- Subscribe to T-Net Direct
Submit News ▼

« Sections »
News
Events
Tech Careers
Directory
Tech Stocks
T-Net 100
Members
Feedback
About T-Net
« Account Login »
Members
Employers
« Services »
Post Job Listings
Browse Jobs
Advertise

News By Company

Xenon Pharmaceuticals Inc.

1 - 10 of 29 Results

New Search

Xenon Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate Update

Burnaby, BC, May 30, 2022--Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, reported financial results for the first quarter ended March 31, 2022 and provided a corporate update.

Snapshot | Profile | News (37) | Follow

Company Snapshot

Xenon Pharmaceuticals Inc.

Burnaby, BC (Biotech/Life Sciences)
100-499 Employees In BC (100-499 Employees Total)
Founded: 1996 | Revenues: $15.60 Million

We are a clinical stage biopharmaceutical company committed to developing innovative therapeutics to improve the lives of patients with neurological disorders.

See Full Profile

Company Alert

Xenon Pharmaceuticals Inc.

Burnaby, BC (Biotech/Life Sciences)

Notify Me

New Job Listings Posted By This Company
News and Editorial Regarding This Company
Company Profile Changes and Updates
Personnel Changes At This Company

Company Alert Notification Settings

Please select how you would like to be notified of updates by this Company:

	Display Updates For This Company in My Member Account Online
	Please Send me an Email Alert (With All of My Company Updates) On The Following Dates:
	(Updates from all selected companies are combined and sent in a single email)

Cancel

Xenon Pharmaceuticals Reports 2021 Financial Results and Provides Corporate Update

Burnaby, BC, March 4, 2022--Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, reported financial results for the year ended December 31, 2021 and provided a corporate update.

Snapshot | Profile | News (37) | Follow

Company Snapshot

See Full Profile

Company Alert

Xenon Pharmaceuticals Inc.

Burnaby, BC (Biotech/Life Sciences)

Notify Me

New Job Listings Posted By This Company
News and Editorial Regarding This Company
Company Profile Changes and Updates
Personnel Changes At This Company

Company Alert Notification Settings

Please select how you would like to be notified of updates by this Company:

	Display Updates For This Company in My Member Account Online
	Please Send me an Email Alert (With All of My Company Updates) On The Following Dates:
	(Updates from all selected companies are combined and sent in a single email)

Cancel

Xenon Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Corporate Update

Burnaby, BC, November 29, 2021--Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, reported financial results for the third quarter ended September 30, 2021 and provided a corporate update.

Snapshot | Profile | News (37) | Follow

Company Snapshot

See Full Profile

Company Alert

Xenon Pharmaceuticals Inc.

Burnaby, BC (Biotech/Life Sciences)

Notify Me

New Job Listings Posted By This Company
News and Editorial Regarding This Company
Company Profile Changes and Updates
Personnel Changes At This Company

Company Alert Notification Settings

Please select how you would like to be notified of updates by this Company:

	Display Updates For This Company in My Member Account Online
	Please Send me an Email Alert (With All of My Company Updates) On The Following Dates:
	(Updates from all selected companies are combined and sent in a single email)

Cancel

Xenon Pharmaceuticals Announces Completion of Patient Randomization in XEN1101 Phase 2b "X-TOLE" Clinical Trial

Burnaby, BC, July 13, 2021--Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, provided an update on its ongoing XEN1101 Phase 2b "X-TOLE" clinical trial, announcing that randomization of 326 patients was completed in late June. Based on completion of patient randomization, Xenon anticipates topline results from the Phase 2b X-TOLE clinical trial in late September to mid-October 2021.

Snapshot | Profile | News (37) | Follow

Company Snapshot

See Full Profile

Company Alert

Xenon Pharmaceuticals Inc.

Burnaby, BC (Biotech/Life Sciences)

Notify Me

New Job Listings Posted By This Company
News and Editorial Regarding This Company
Company Profile Changes and Updates
Personnel Changes At This Company

Company Alert Notification Settings

Please select how you would like to be notified of updates by this Company:

	Display Updates For This Company in My Member Account Online
	Please Send me an Email Alert (With All of My Company Updates) On The Following Dates:
	(Updates from all selected companies are combined and sent in a single email)

Cancel

Xenon Pharmaceuticals Provides Corporate Update and Confirms New President and CEO Following Annual Meeting of Shareholders

Burnaby, BC, June 7, 2021--Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, provided a corporate update following its 2021 Annual Meeting of Shareholders held on June 3, 2021.

Snapshot | Profile | News (37) | Follow

Company Snapshot

See Full Profile

Company Alert

Xenon Pharmaceuticals Inc.

Burnaby, BC (Biotech/Life Sciences)

Notify Me

New Job Listings Posted By This Company
News and Editorial Regarding This Company
Company Profile Changes and Updates
Personnel Changes At This Company

Company Alert Notification Settings

Please select how you would like to be notified of updates by this Company:

	Display Updates For This Company in My Member Account Online
	Please Send me an Email Alert (With All of My Company Updates) On The Following Dates:
	(Updates from all selected companies are combined and sent in a single email)

Cancel

Xenon Pharmaceuticals Announces Collaboration with Researchers at Icahn School of Medicine at Mount Sinai to Conduct a Phase 2 Study of XEN1101

Burnaby, BC, March 23, 2021--Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical stage biopharmaceutical company, has announced a collaboration with the Icahn School of Medicine at Mount Sinai (Mount Sinai) to facilitate an investigator-sponsored Phase 2 proof-of-concept, randomized, parallel-arm, placebo-controlled clinical trial of XEN1101 for the treatment of major depressive disorder (MDD) and anhedonia, which is an inability to feel pleasure.

Snapshot | Profile | News (37) | Follow

Company Snapshot

See Full Profile

Company Alert

Xenon Pharmaceuticals Inc.

Burnaby, BC (Biotech/Life Sciences)

Notify Me

New Job Listings Posted By This Company
News and Editorial Regarding This Company
Company Profile Changes and Updates
Personnel Changes At This Company

Company Alert Notification Settings

Please select how you would like to be notified of updates by this Company:

	Display Updates For This Company in My Member Account Online
	Please Send me an Email Alert (With All of My Company Updates) On The Following Dates:
	(Updates from all selected companies are combined and sent in a single email)

Cancel

Xenon Pharmaceuticals Reports 2020 Financial Results and Provides Corporate Update

Burnaby, BC, March 2, 2021--Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, reported financial results for the year ended December 31, 2020 and provided a corporate update.

Snapshot | Profile | News (37) | Follow

Company Snapshot

See Full Profile

Company Alert

Xenon Pharmaceuticals Inc.

Burnaby, BC (Biotech/Life Sciences)

Notify Me

New Job Listings Posted By This Company
News and Editorial Regarding This Company
Company Profile Changes and Updates
Personnel Changes At This Company

Company Alert Notification Settings

Please select how you would like to be notified of updates by this Company:

	Display Updates For This Company in My Member Account Online
	Please Send me an Email Alert (With All of My Company Updates) On The Following Dates:
	(Updates from all selected companies are combined and sent in a single email)

Cancel

Xenon Pharmaceuticals Outlines Key Milestone Opportunities and Planned Leadership Transition in 2021

Burnaby, BC, January 19, 2021--Xenon Pharmaceuticals Inc.(Nasdaq:XENE), a neurology-focused biopharmaceutical company, outlined its key milestone opportunities and plans for a leadership transition in 2021, with all changes anticipated to take effect in June 2021 at the time of the Company's annual meeting of shareholders.

Snapshot | Profile | News (37) | Follow

Company Snapshot

See Full Profile

Company Alert

Xenon Pharmaceuticals Inc.

Burnaby, BC (Biotech/Life Sciences)

Notify Me

New Job Listings Posted By This Company
News and Editorial Regarding This Company
Company Profile Changes and Updates
Personnel Changes At This Company

Company Alert Notification Settings

Please select how you would like to be notified of updates by this Company:

	Display Updates For This Company in My Member Account Online
	Please Send me an Email Alert (With All of My Company Updates) On The Following Dates:
	(Updates from all selected companies are combined and sent in a single email)

Cancel

Xenon Pharmaceuticals Provides Updates on Neurology Pipeline Programs

Burnaby, BC, December 16, 2020--Xenon Pharmaceuticals Inc.(Nasdaq:XENE), a neurology-focused biopharmaceutical company, announced updates on its proprietary and partnered neurology programs at AES2020, the virtual Annual Meeting of the American Epilepsy Society.

Snapshot | Profile | News (37) | Follow

Company Snapshot

See Full Profile

Company Alert

Xenon Pharmaceuticals Inc.

Burnaby, BC (Biotech/Life Sciences)

Notify Me

New Job Listings Posted By This Company
News and Editorial Regarding This Company
Company Profile Changes and Updates
Personnel Changes At This Company

Company Alert Notification Settings

Please select how you would like to be notified of updates by this Company:

	Display Updates For This Company in My Member Account Online
	Please Send me an Email Alert (With All of My Company Updates) On The Following Dates:
	(Updates from all selected companies are combined and sent in a single email)

Cancel

Xenon Pharmaceuticals Receives FDA Feedback and is on Track to Initiate XEN496 Phase 3 Clinical Trial for the Treatment of KCNQ2-DEE

Burnaby, BC, October 9, 2020--Xenon Pharmaceuticals Inc.(Nasdaq:XENE), a neurology-focused biopharmaceutical company, provided regulatory updates on its proprietary pediatric neurology program, XEN496, a Kv7 potassium channel modulator that is a proprietary pediatric formulation of the active ingredient ezogabine being developed for the treatment of KCNQ2 developmental and epileptic encephalopathy (KCNQ2-DEE).

Snapshot | Profile | News (37) | Follow

Company Snapshot

See Full Profile

Company Alert

Xenon Pharmaceuticals Inc.

Burnaby, BC (Biotech/Life Sciences)

Notify Me

New Job Listings Posted By This Company
News and Editorial Regarding This Company
Company Profile Changes and Updates
Personnel Changes At This Company

Company Alert Notification Settings

Please select how you would like to be notified of updates by this Company:

	Display Updates For This Company in My Member Account Online
	Please Send me an Email Alert (With All of My Company Updates) On The Following Dates:
	(Updates from all selected companies are combined and sent in a single email)

Cancel

1 2 3

Hiring Today

See All Jobs

Latest Tech Jobs

Featured Job: Manager, NetSuite ERP

Global Relay Communications Inc.

Senior Database Administrator

ESIT Advanced Solutions

Production Operator

Svante Inc.

Global Director of Product Safety

Ballard Power Systems Inc.

Digital Customer Success Manager

Alida (formerly Vision Critical)

See All Jobs

Registration on or use of this website constitutes acceptance of our Terms of Use.

News
BC Tech News ▼
- Local BC Tech News
- One Week View
- Subscribe to T-Net Direct
International ▼
- All Breaking International Tech News
- Tech Crunch
- Silicon Alley Insider
- VentureBeat
- CNET
Member Tools ▼
- Subscribe to T-Net Direct
Submit News ▼
- Post News Release on T-Net
- Submit Anonymous News Tip
- T-Net News Submission Guidelines
Account
Member Login
Employer Login
Sections
News
- BC Tech News ▼
- International ▼
- Member Tools ▼
  - Subscribe to T-Net Direct
- Submit News ▼
Events
- All BC Tech Events ▼
- Member Tools ▼
- Post Events ▼
Tech Careers
- Tech Careers Home
- Job Search ▼
- Hot Job of the Week TM
- Post Resume ▼
  - Post Resume
  - Create Cover Letter
- Member Tools ▼
- Employers ▼
  - Employer Login
  - Post New Job
Directory
- Tech Directory Home
- Companies ▼
- Suppliers ▼
- Associations ▼
- Add Profile ▼
Tech Stocks
- BC Tech Stocks ▼
- T-Net 20 Stock Index
- Member Tools ▼
  - Stock Alerts
  - Company Search
- Add Company ▼
  - Add Company
T-Net 100
- T-Net 100 Rankings ▼
- Sector Rankings ▼
- Advertising
Members
- Member Home ▼
- News ▼
- Events ▼
- Careers ▼
- Directory ▼
- Other ▼
Feedback
About T-Net
Services
Post Job Listings
Advertise on T-Net